Skip to main content

Proven efficacy for MANAGING inflammation and pain associated with cataract surgery1,2

PERCENTAGE OF PATIENTS WITH INFLAMMATION COMPLETELY RESOLVED AT DAY 141

STUDY 11,2

P<0.05 for ILEVRO® vs vehicle2

STUDY 21,2

P<0.05 for ILEVRO® vs vehicle2

STUDY 11,2

P<0.05 for ILEVRO® vs vehicle2

STUDY 21,2

P<0.05 for ILEVRO® vs vehicle2

VIEW STUDY DESIGN

In both of these studies

> 2 x

as many ILEVRO® patients had complete resolution vs vehicle1

Use more than 1 day before surgery or use beyond 14 days after surgery may increase patient risk and severity of corneal adverse events.1

PAIN FREE AS EARLY AS DAY 11

Percentages of ILEVRO®-treated patients who experienced mild to no pain in both studies3,4

No painDiscomfortMild painModerate painModerately severe pain 76% 19% 3% 1% 1%
No painDiscomfortMild painModerate painModerately severe pain 76% 19% 3% 1% 1%

 

 

n=894

VIEW STUDY DESIGN

In both of these studies

> 98 %

of patients treated with ILEVRO ® experienced mild to no pain at post-op day 1 3,4

Designed for potency and penetration1

Your patients may be able to save on their prescription

Data provided through MMIT and are current as of 7/24/2023. The information provided in this website is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein.

Defined as zero cells and zero flare on a scale of 0 (none) to 4 (>30 cells) and 0 (no visible flare) to 3 (severe), respectively.3

Nevanac® vehicle percentage calculated using the ITT population.3

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40(2):203-211. 3. Data on file. Clinical Overview. Harrow IP, LLC; 2023. 4. Data on file. Summary Review. Harrow IP, LLC; 2023.

References: 1. ILEVRO (nepafenac ophthalmic suspension) 0.3% [package insert]. Harrow IP, LLC; 2023. 2. Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40(2):203-211. 3. Data on file. Clinical Overview. Harrow IP, LLC; 2023. 4. Data on file. Summary Review. Harrow IP, LLC; 2023.